Comprehensive study exposes critical health risks of obesity, including diabetes, heart disease, and cancer, while offering ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

The Swiss pharmaceutical company has set a high bar for any potential obesity-treatment acquisition as it scans the market ...

Wave Life Sciences (NASDAQ:WVE) announced clinical trial application approval and initiation of the Phase 1 INLIGHT clinical ...

Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the company announced Feb. 4. Amgen has not detailed ...